Andrew Gengos - Jun 7, 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Officer
Signature
/s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Stock symbol
ATHA
Transactions as of
Jun 7, 2023
Transactions value $
$51,445
Form type
4
Date filed
6/9/2023, 05:06 PM
Previous filing
Jun 6, 2023
Next filing
Jan 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Purchase $1.42K +422 +0.65% $3.36 65.4K Jun 7, 2023 Direct F1
transaction ATHA Common Stock Purchase $9.72K +2.86K +4.37% $3.40 68.3K Jun 7, 2023 Direct
transaction ATHA Common Stock Purchase $40.3K +11.7K +17.16% $3.44 80K Jun 7, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $3.355 to $3.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $3.43 to $3.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Remarks:

Chief Financial Officer and Chief Business Officer